Prognostic utility of negative stress/rest myocardial SPECT studies among patients with different clinical categories of chronic kidney disease: Data from an Egyptian cohort  by Mandour Ali, Mohamed A. & Sabry, Haitham
The Egyptian Heart Journal (2016) 68, 187–192HO ST E D  BY
Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comORIGINAL ARTICLEPrognostic utility of negative stress/rest myocardial
SPECT studies among patients with diﬀerent
clinical categories of chronic kidney disease: Data
from an Egyptian cohortAbbreviations: BMI, Body mass index; CD, cardiac death; CKD, chronic kidney disease; EF%, ejection fraction; eGFR, estimated glo
filtration rate; HF, heart failure; LHR, lung heart ratio; LV, left ventricle; LVED volume, LV end-diastolic volume; LVES volume, LV end
volume; LVH, left ventricular hypertrophy; METs, metabolic equivalents; MI, myocardial infarction; MPI, myocardial perfusion imagin
negative predictive value; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronar
bypass surgery; SD, standard deviation; SPECT, single photon emission computed tomography; SSS, summed stress score; SRS, summ
score; SDS, summed difference score; STEMI, ST elevation myocardial infarction
* Corresponding author at: Department of Cardiology, Al-Azhar School of Medicine, 10 Hassan Mamoun St., Cairo 11391, Egypt. T
1000890905.
E-mail address: mmandour2009@gmail.com (M.A. Mandour Ali).
Peer review under responsibility of Egyptian Society of Cardiology.
http://dx.doi.org/10.1016/j.ehj.2016.02.002
1110-2608  2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Mohamed A. Mandour Ali *, Haitham SabryCardiology and Internal Medicine/Nephrology Departments, Al-Azhar School of Medicine, Cairo, EgyptReceived 29 June 2015; accepted 1 February 2016
Available online 23 February 2016KEYWORDS
NPV;
SPECT;
Outcome research;
CKDAbstract Prognostic value of negative myocardial SPECT study is well established. However,
patients with chronic kidney disease (CKD) are a special group showing increased risk of cardiac
events. We thought to investigate the prognostic value of negative SPECT study among patients
on regular hemodialysis compared to other clinical categories of CKD.
Methods: 186 consecutive patients with CKD and negative SPECT study were enrolled. 93 (50%)
were on hemodialysis with an eGFR< 30 mL/min/1.73 m2 (Group I); 25 (13.4%) had uncompli-
cated renal transplantation with eGFR between 45 and 90 mL/min/1.73 m2 (Group II) and 68
(36.6%) with CKD on conservative management and no prior history of hemodialysis (eGFR
between 30 and 60 mL/min/1.73 m2), Group (III). End points (CD, STEMI/NSTEMI, need for
revascularization and hospitalized HF) were traced at 6 months, one year and 2 years.
Results: Total events in all groups were 5 (2.70%) at 6 months, and 18 (9.70%) and 36 (19.30%) at
one year and 2 years respectively. At one year 16 (17.20%) cardiac events happened in Group I
compared to one (4.0%) and one (1.50%) event(s) in Groups II and III respectively (p values
0.001). At 2 years, 29 (31.20%) cardiac events happened in Group I while 2 (8.0%) and 5
(7.30%) happened in Groups II and III respectively (p values 0.01, 0.001 respectively). eGFR
and duration of hemodialysis were the independent predictors of cardiac events.merular
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188 M.A. Mandour Ali, H. SabryConclusion: Despite negative MPI study, patients on hemodialysis showed higher event (including
CD, STEMI/NSTEMI and revascularization) rate at one and 2 years of follow-up compared to
other clinical categories of CKD.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Negative predictive value (NPV) of SPECT scans for detection
of myocardial infarction (MI) and cardiac death (CD) was
shown to be in the neighborhood of 98.8% (95% confidence
interval [CI] 98.5–99.0) during 36 months of follow-up.1
Patients with chronic kidney disease (CKD) are at increased
risk of early and progressive coronary artery disease (CAD).2
Data coming from Egyptian centers discussing value of
SPECT in patients with CKD are lacking. Hence, we thought
to evaluate the prognostic value of negative SPECT studies
among Egyptian patients on regular hemodialysis compared
to other clinical categories of CKD.
2. Methods
2.1. Study cohort
The study cohort consisted of 193 consecutive patients referred
for 99mTc sestamibi gated SPECT study at Al-Azhar school of
medicine (Cairo, Egypt), and Alfa scan center (Heliopolis,
Cairo, Egypt) nuclear cardiac laboratories between September
2011 and May 2013. Seven patients were excluded due to non-
cardiac deaths during the follow-up period. All enrolled
patients had a documented CKD. The study population was
divided into 3 groups according to the main treatment received
for CKD. Group (I), 93 patients (50%) were on regular
hemodialysis with an eGFR< 30 mL/min/1.73 m2. Group
(II), 25 patients (13.4%) had uncomplicated renal transplanta-
tion surgery after variable period of hemodialysis with eGFR
values between 45 and 90 mL/min/1.73 m2. Group (III), 68
patients (36.6%) had CKD (eGFR between 30 and 60 mL/
min/1.73 m2) on conservative medical management of CKD
and no prior history of hemodialysis. Mean period of
hemodialysis among Group I was 3 ± 2.2 years while mean
period of hemodialysis among Group II before renal trans-
plantation surgery was 2.5 ± 1.9 years.
All patients enrolled on this study had a negative myocar-
dial SPECT study. All patients with quantitatively and qual-
itatively normal myocardial perfusion on SPECT, who
showed any other high risk non-perfusion abnormalities
(e.g. namely stress induced LV cavity dilatation and stress
induced myocardial stunning), were excluded for sake of
reproducibility. All patients with advanced comorbidities
(e.g. cancer, advanced liver failure) were also excluded.
Patients post-renal transplantation with rejection (acute, sub-
acute or chronic) who are currently on regular dialysis were
excluded for sake of reproducibility. Patients with
echocardiographic data of significant valvular heart disease,
pericardial disease or LV systolic dysfunction (EF%
< 50%) were also excluded.2.2. Stress protocol
A total of 109 (58.6%) patients underwent treadmill exercise
stress according to the standard Bruce protocol. 77 (41.4%)
had pharmacologic stress using Dipyridamole according to
the standard infusion protocol.7,8 Stress testing was
symptom-limited. Premature termination of the stress test
was done according to the recommendations in the updated
guidelines of exercise testing.7,8
2.3. Myocardial perfusion imaging
All subjects underwent a gated-SPECT MPI according to a
two-day protocol. Supine images were acquired with a dual-
head (Philips JetStream or Siemens WorkSpace cameras) with
low-energy, high-resolution collimators. All radionuclide
images and associated data were processed according to the
standard protocols. 99mTc sestamibi was used in all patients
(the routine tracer used in our laboratories). Myocardial perfu-
sion was calculated as a relative percent of tracer uptake in the
standard model ‘‘17 segment model”.8
Experienced nuclear cardiology specialists used these data
on a semi-quantitative approach to interpret each MPI study.
Readers assigned a score (0–4) to each segment: (0) for normal
uptake; (1, 2 and 3) for mild, moderate and severe reduction of
uptake respectively; and (4) for absent uptake. Sum stress
score (SSS), sum rest score (SRS) and sum difference score
(SDS) were reported. Other markers of high risk perfusion
scans were reported separately (e.g. increased LHR, Transient
LV cavity dilatation, abnormal regional and global wall
motion abnormalities). Negative SPECT study was defined
as SSS < 4 and SDS = 0.
2.4. Follow-up data
6 months, one year and 2 years follow-up data were collected
through telephone calls and hospital records. End points were
cardiac death, STEMI/NSTEMI, the need for revasculariza-
tion procedure and documented HF.
2.5. Statistical analysis
Continuous variables were expressed as mean and SD, and cat-
egorical variables were expressed as percentages. Student’s
t-tests were used to compare the groups in view of different
clinical and MPI data. The primary end point was the occur-
rence of cardiac events, defined as cardiac death, nonfatal
MI, need for revascularization procedure and documented
HF. Cox regression hazard analysis was used to assess the
impact of different demographic and clinical data. p value of
less than 0.05 was considered significant. Statistical analysis
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JMP4.0 (SAS Institute Inc.); SPSS 16.0 (SPSS Inc).
3. Results
Demographic characteristics of the study cohort are presented
in Table 1.
All myocardial SPECT studies were reported as negative for
evidence of myocardial ischemia (mean SSS, SRS and SDS
were 2 ± 1, 1 ± 1 and 0 for the three groups). As shown in
Table 1 differences between different groups as regards LVES
and LVED volumes and EF% were very insignificant. Primary
end points (cardiac death and STEMI/NSTEMI, need for
revascularization and documented HF) were traced at
6 months, one year and two years of follow-up (see Tables 2–4).
At 6 months follow-up; 5 (2.70%) total cardiac events hap-
pened: one (0.50%) STEMI/NSTEMI, 4 (2.40%) HF necessi-
tating hospitalization. No cardiac deaths happened at
6 months of follow-up.
Group I showed one (1.10%) STEMI/NSTEMI and 2
(2.15%) HF necessitating hospitalization. Groups II and III
showed one HF event (4%) and (1.47%) respectively,Table 1 Demographic and clinical characteristics of the study
cohort.
Total number of study population 186 patients
Mean age 56 ± 11 years
Male sex 113 (61.0%)
DM 136 (73.0%)
HTN 158 (85.0%)
Dyslipidemia 109 (59.0%)
BMI (kg/m2) 20–25 119 (64.0%)
BMI (kg/m2) 25–35 51 (27.0%)
BMI (kg/m2) > 35 16 (9.0%)
Abnormal baseline ECG 165 (89.0%)
Mean exercise duration (mins) 6.5 ± 2.9
Mean workload (METs) 7.9 ± 1.2
Cause of termination
 Leg fatigue 47 (25.0%)
 Significant SOB 46 (25.0%)
 Significant chest pain 16 (9.0%)
 Injection of pharmacologic agent 77 (41.0%)
LVH (IVS > 1.5 mm) 56 (30.0%)
LVH (IVS 1.3–1.5 mm) 101 (54.0%)
LVH (IVS < 1.3 mm) 29 (16.0%)
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Figure 1 Cardiac events during the follow-up period among
study groups.(p value = 0.57). No STEMI/NSTEMI events occurred
among Groups II and III at 6 months of follow-up. A negative
myocardial SPECT study showed an excellent predictive value
for cardiac events among all patients with CKD at 6 months of
follow-up.
At one year of follow-up; 18 (9.70%) total cardiac events
happened (5 STEMI/NSTEMI, 12 HF necessitating hospital-
ization and one revascularization event). Group I showed 2
(5.40%) STEMI/NSTEMI, 10 (10.70%) HF necessitating hos-
pitalization and one (1.10%) revascularization event. Groups
II and III showed one HF event (4.0%) and (1.50%)
respectively.
Patients on regular hemodialysis showed a higher rate of
STEMI/NSTEMI compared to the other 2 groups at one year
of follow-up. Differences were of borderline statistical signifi-
cance (p value = 0.06). HF requiring hospitalization was sta-
tistically higher among patients on regular hemodialysis
compared to the other 2 groups (p value <0.01 and 0.0001
respectively). No cardiac deaths occurred among the study
population at one year of follow-up.
Figure 1 shows the total cardiac events among study groups
at 6 months, one year and two years of follow up.
At two years of follow-up; 36 (19.3%) total cardiac events
happened (2 cardiac deaths, 11 STEMI/NSTEMI, 18 HF
necessitating hospitalization, 5 revascularization events).
Group I showed 2 (2.15%) cardiac deaths, 9 (9.7%) STEMI/
NSTEMI, 14 (15.0%) HF necessitating hospitalization and 4
(4.3%) revascularization events. Group II showed one
(4.0%) STEMI/NSTEMI and one (4.0%) HF event. Group
III showed one (1.50%) STEMI/NSTEMI, 3 (4.50%) HF
and one (1.50%) revascularization events. Patients on regular
hemodialysis had a higher statistically significant cardiac event
rates compared to the other 2 groups at 2 years of follow-up
(p values <0.01 and <0.0001 respectively).
Univariate cox regression analysis showed that eGFR and
duration of hemodialysis are the only predictors of cardiac
events among the studied cohort. This study cohort is a rela-
tively low risk cohort owing to the fact that all patients
included in this study had negative MPI results, normal LV
dimensions and LVEF%.4. Discussion
MPI study is a well-established prognostic tool for effective
cardiovascular risk stratification among the general popula-
tion. Renal dysfunction is also an important independent pre-
dictor of cardiac death among patients with significant
ischemia burden (moderate to large perfusion defects on
MPI studies). Annualized hard cardiac event rate among
patients with normal MPI studies is in the range of
0.2–0.8%. However, most MPI prognostic studies and large
clinical trials have not included kidney function in their
analyses.3–6 Hence, we thought to investigate the cardiac event
rate among an Egyptian cohort with CKD in different stages
of the disease according to eGFR.
Our results point to a statistically significant difference in
cardiac events including non-fatal MI and need for revascular-
ization procedures at one and 2 years of follow-up after a neg-
ative MPI study among hemodialysis patients compared to
other clinical categories of CKD. It also confirmed that eGFR
value and duration of CKD were the independent predictors of
Table 2 Demographic and clinical characteristics of the study groups.
Group I = hemodialysis Group II = post renal transplant Group III = CRI p value
Number 93 (50%) 25 (13.4%) 68 (36.6%)
Mean age (years) 55 ± 9 54 ± 7 55 ± 6
Male sex 59 (63.0%) 15 (60.0%) 39 (57.0%)
DM 67 (72.0%) 18 (72.0%) 51 (75.0%) p= 0.59
HTN 79 (85.0%) 21 (84.0%) 58 (85.0%) p= 0.66
Dyslipidemia 55 (60.0%) 14 (52.0%) 40 (58.0%) p= 0.57
Period of hemodialysis (years) 3 ± 2.2 2.5 ± 1.9 –
BMI (kg/m2) 20–25 59 (64.0%) 16 (64.0%) 44 (65.0%) p= 0.81
BMI (kg/m2) 25–35 27 (29.0%) 7 (28.0%) 17 (25.0%) p= 0.67
BMI (kg/m2) > 35 7 (7.5%) 2 (8.0%) 7 (10.0%) p= 0.88
Abn. baseline ECG 81 (87.0%) 22 (88.0%) 62 (91.0%) p= 0.94
Mean Ex. Time (mins) 6.5 ± 1.2 7.1 ± 1 6.9 ± 1.3 p= 0.63
Mean workload (METs) 8 ± 1 9 ± 1 9 ± 1 p= 0.54
Cause of termination
 Leg fatigue 31 (33.0%) 9 (36.0%) 7 (10.0%)
 Significant SOB 27 (29.0%) 6 (24.0%) 13 (19.0%)
 Chest pain 8 (8.60%) 2 (8.0%) 6 (8.80%)
 Injection of pharmacologic agent 27 (29.0%) 8 (32.0%) 42 (61.0%)
Table 3 Cardiac events during the follow-up period in different groups.
Group I Group II Group III
6 months follow-up data
 Cardiac death 0 0 0
 STEMI/NSTEMI 1 (1.0%) 0 0 p value = 0.83
 HF 2(2.0%) 1 (4.0%) 1 (1.50%) p value = 0.59
 PCI/CABG 0 0 0
 PCI/CABG 0 0 0
1 year follow-up data
 Cardiac death 0 0 0
 STEMI/NSTEMI 5 (5.40%) 0 0
 HF 10 (10.70%) 1 (4.0%) 1 (1.50%) p value = 0.017
 PCI/CABG 1 (1.0%) 0 0
2 years follow-up
 Death 2 (2.20%) 0 0 p value = 0.002
 STEMI/NSTEMI 9 (9.70%) 1 (4.0%) 1 (1.50%) p value = 0.05
 HF 14 (15.0%) 1 (4.0%) 3 (4.50%) p value = 0.001
 PCI/CABG 4 (4.30%) 0 1 (1.50%) p value = 0.015
Table 4 Univariate cox regression analysis of different
demographic and clinical data affecting outcomes.
Variable Hazard
ratio
CI (95%) p value
Mean age 1.29 0.33–2.21 0.69
Male sex 0.77 0.99–1.77 0.77
DM 3.99 0.9–11.2 0.45
BMI (kg/m2) > 30 2.8 1.54–7.55 0.66
HTN 3.47 1.05–9.98 0.89
eGFR (mL/min/1.73 m2) < 30 0.91 0.9–0.99 0.0004
Mean duration of HD (years) > 3 0.88 0.78–0.92 0.001
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tive MPI study, hard cardiac event rate including cardiac death
appeared higher among patients on regular hemodialysis than
patients with chronic renal impairment on conservative
protocol or recipients of successful renal transplant. This cor-relates with multiple reports emphasizing the deleterious effect
of lower eGFR on incidence and severity of myocardial ische-
mia and subsequently on cardiac event rate.
Al-Mallah et al. studied a big cohort of patients with differ-
ent stages of CKD referred for MPI study, and correlated MPI
results to level of eGFR. Those with eGFR< 30 mL/
min/1.73 m2 were 256 patients. They demonstrated a close
interaction between renal function and the magnitude of perfu-
sion deficit as assessed by stress MPI such that mortality rates
almost double among patients with moderate or severe renal
impairment (GFR< 60 mL/min/1.73 m2) in the presence of
abnormal stress nuclear scans.9,10
Hakeem et al. reported that patients with normal MPI but
with CKD had a significantly higher CD rate (2.7% per year)
than those with normal MPI and no CKD (0.8% per year).
The survival probabilities for patients with CKD alone (nor-
mal MPI) and abnormal MPI alone (no CKD) were similar.
This means that event free survival after a negative MPI in
Prognostic utility of negative stress/rest myocardial SPECT studies 191the absence of CKD seemed to be different if compared to
those with negative MPI in the presence of CKD.11
Our results also correlate with the results of Furuhashi et al.
They studied 108 Japanese patients with CKD defined as
eGFR< 60 mL/min/1.73 m2 with normal MPI studies and no
history of hemodialysis or CAD. They concluded that normal
stress MPI cannot guarantee an event free survival for patients
with CKD. They followed up this cohort over a mean period
of 24 months and concluded that the cardiac event rate was
7%. The following were determined as significant predictors of
cardiac events: age, hemoglobin levels, eGFR, SSS, and SDS.12
However, our results point to a significantly higher inci-
dence of total cardiac events (2.68%, 8.06% and 20.9%) at
6 months, one year and two years of follow-up respectively.
CD and STEMI/NSTEMI were also significantly higher at
2 years of follow-up after a negative MPI study (2.15% and
9.7% respectively). The poorer kidney function might explain
the relatively higher cardiac events in our cohort compared to
Japanese cohort (50% of our cohort had eGFR <mL/
min/1.73 m2).
Again, Furuhashi et al. suggested that after a negative MPI
study, follow-up MPI should be indicated within 1–2 years.
However, our results point to the need for much closer MPI
follow-up studies particularly among those patients on regular
hemodialysis. Also, more aggressive medical control should be
planed and strictly observed.12
Multiple reports evaluating prevalence of CAD in dialysis
patients using myocardial perfusion imaging coming from dif-
ferent ethnic groups found significant variations. Majeed et al.
in a Pakistanian cohort of 100 consecutive patients with ESRD
in the waiting list for renal transplantation showed that the
prevalence of positive MPI results among the study population
was 47%.13 Kim et al. in a Korean cohort of 227 patients
recently starting renal dialysis showed that the prevalence of
positive MPI was 22.5%.14 Stack et al. studied 4025 patients
with ESRD in United States and showed that the prevalence
of positive MPI was 38%. The presence of moderate to large
perfusion defects among patients with ESRD had an incremen-
tal prognostic effect than either alone.15 All reports confirmed
the finding that positive MPI result in the setting of ESRD is
associated with higher cardiac morbidity and mortality.
Multiple mechanisms have been suggested to explain the
increased mortality rates in patients with CKD. These mecha-
nisms include anemia, increased oxidative stresses, derange-
ments in calcium-phosphate homeostasis, inflammation,
ventricular loading conditions and coagulation tendency.
Indeed, the rapid progression of atherosclerotic vascular dis-
ease among patients with CKD is well-established in literatures.
Beyond this, the increased cardiac event rate among hemodial-
ysis patients was primarily explained by the enhanced myocar-
dial and arterial remodeling, predominantly secondary to
pressure and volume overload. Pressure overload results from
the frequent association of uncontrolled HTN, aortic stenosis
and anemia, resulting in concentric LVH. Volume overload is
the result of arteriovenous shunting, salt and water overload,
anemia and hypoalbuminemia resulting in left ventricular dila-
tion. The process of concentric and subsequently eccentric
LVH ultimately ends in congestive (mostly, refractory) heart
failure and arrhythmogenic complications. Endothelial dys-
function, microcirculatory abnormalities and abnormal coro-
nary reserve are important pathophysiologic mechanisms.15–24In an outstanding work done by Fukushima et al., they
studied a group of CKD patients for evidence of inducible
ischemia and quantification of global and regional absolute
myocardial blood flow (MBF) by PET imaging. They reported
that even among those with normal clinical myocardial perfu-
sion by PET scan, patients with CKD had reduced global
myocardial flow reserve, which implied an underlying
microvascular dysfunction in this population that could
explain the poorer prognosis.255. Conclusion
Patients on regular hemodialysis had a higher statistically sig-
nificant cardiac event rate compared to the other clinical cate-
gories of CKD at one year and 2 years of follow-up.
Subsequently, a more rigorous approach of follow-up should
be applied among hemodialysis patients. The lower is the
eGFR and longer is the hemodialysis duration the higher is
the cardiac event rate.6. Recommendation
A large volume study from different Egyptian centers should
be conducted to estimate the follow-up duration applicable
for each clinical category of CKD based on eGFR values.Conﬂict of interest
None declared.References
1. Metz LD, Beattie M, Hom R, et al. The prognostic value of
normal exercise myocardial perfusion imaging and exercise
echocardiography: a meta-analysis. J Am Coll Cardiol 2007;49
(2):227–37, January 16.
2. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline
update for perioperative cardiovascular evaluation for non-cardiac
surgery. J Am Coll Cardiol 2002;39:542–53.
3. Okwuosa T, Williams KA. Coronary artery disease and nuclear
imaging in renal failure. J Nucl Cardiol 2006;13:150–5.
4. Yao Q, Pecoits-Filho R, Lindholm B, et al. Traditional and
nontraditional risk factors as contributors to atherosclerotic
cardiovascular disease in end-stage renal disease. Scand J Urol
Nephrol 2004;38:405–16.
5. Coceani M, Gimelli A, Carpeggiani C, L’abbate A, Marzullo P.
Clinical utility of estimated glomerular filtration rate in patients
undergoing gated SPECT. J Nucl Cardiol 2009;16.
6. Werkhoven JM, Schuijf JD, Gaemperli O, et al. Prognostic value
of multislice computed tomography and gated single-photon
emission computed tomography in patients with suspected coro-
nary artery disease. J Am Coll Cardiol. 2009 February 17;53
(7):623–32.
7. Gibbons RJ, Balady GJ, Bricker JT, et al. American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines. Committee to Update the 1997 Exercise Testing
Guidelines. ACC/AHA 2002 guideline update for exercise testing:
summary article. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
Committee to Update the 1997 Exercise Testing Guidelines. J Am
Coll Cardiol 2002;40:1531–40.
192 M.A. Mandour Ali, H. Sabry8. Henzlova MJ, Cerqueira MD, Hansen CL, et al. ASNC imaging
guidelines for nuclear cardiology procedures; stress protocols and
tracers. J Nucl Cardiol 2009;1071–3581.
9. Okuyama O, Nakajima K, Hatta T, et al. Incremental prognostic
value of myocardial perfusion single photon emission computed
tomography for patients with diabetes and chronic kidney disease.
Nucl Med Commun 2011 October;32(10):913–9.
10. Al-Mallah MH, Hachamovitch R, Dorbala S, et al. Incremental
prognostic value of myocardial perfusion imaging in patients
referred to stress single-photon emission computed tomography
with renal dysfunction. Circ Cardiovasc Imaging 2009;2:429–36.
11. Hakeem A, Bhatti S, Dillie KS, et al. Predictive value of
myocardial perfusion single-photon emission computed tomogra-
phy and the impact of renal function on cardiac death. Circulation
2008;118:2540–9.
12. Furuhashi T, Moroi M, Joki N, et al. Prediction of cardiovas-
cular events in pre-dialysis chronic kidney disease patients with
normal SPECT myocardial perfusion imaging. J Cardiol
2014;63:154–8.
13. Majeed I, Ayub M, Abid A, Azhar M. Predictors of positive
thallium 201 single photon emission computed tomography in
patients with end stage renal disease. J Ayub Med Coll Abbottabad
2008;20(1).
14. Kim SB, Lee SK, Park JS, Moon DH. Prevalence of coronary
artery disease using thallium-201 single photon emission computed
tomography among patients newly undergoing chronic peritoneal
dialysis and its association with mortality. Am J Nephrol
2004;24:448–52.
15. Stack AG, Bloembergen WE. Prevalence and clinical correlates
of coronary artery disease among new dialysis patients in the
United States: a cross-sectional study. J Am Soc Nephrol
2001;12:1516–23.16. Nakajima K, Matsuo S, Okuyama C, et al. Cardiac event risk in
Japanese subjects estimated using gated myocardial perfusion
imaging, in conjunction with diabetes mellitus and chronic kidney
disease. Circ J 2012;76:168–75.
17. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial
perfusion SPECT. J Nucl Cardiol 2004;11:171–85.
18. Bom MJ, Manders JM, Uijlings R, et al. Negative predictive value
of SPECT for the occurrence of MACE in a medium-sized clinic in
the Netherlands. Neth Heart J 2014;22:151–7.
19. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T,
Danesh J, Gudnason V. Chronic kidney disease and risk of major
cardiovascular disease and non-vascular mortality: prospective
population based cohort study. BMJ 2010;341:c4986.
20. Mark PB, Johnston N, Groenning BA, et al. Redefinition of
uremic cardiomyopathy by contrast-enhanced cardiac magnetic
resonance imaging. Kidney Int 2006;69:1839–45.
21. Nakajima K, Nishimura T. Cardiovascular events in Japan:
lessons from the J-ACCESS multicenter prognostic study using
myocardial perfusion imaging. Circ J 2012;76:1313–21.
22. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary
atherosclerotic lesions in patients with end-stage renal failure.
Nephrol Dial Trans 2000;15:218–23.
23. Moe SM, Chen NX. Pathophysiology of vascular calcification in
chronic kidney disease. Circ Res 2004;95:560–7.
24. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification
inhibitors in the pathogenesis of vascular calcification in chronic
kidney disease (CKD). Kidney Int 2005;67:2295–304.
25. Fukushima K, Javadi MS, Higuchi T, et al. Impaired global
myocardial flow dynamics despite normal left ventricular function
and regional perfusion in chronic kidney disease: a quantitative
analysis of clinical 82Rb PET/CT studies. J Nucl Med 2012;53
(6):887–93.
